Clinical Study

Partial Splenic Embolization with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Accompanied by Thrombocytopenia

Yoshihiko Ooka, Tetsuhiro Chiba, Sadahisa Ogasawara, Tenyu Motoyama, Eiichiro Suzuki, Akinobu Tawada, Fumihiko Kanai, and Osamu Yokosuka

Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan

Correspondence should be addressed to Tetsuhiro Chiba; techiba@faculty.chiba-u.jp

Received 2 July 2014; Revised 31 August 2014; Accepted 2 September 2014; Published 15 September 2014

Background. Thrombocytopenia often makes the introduction of systemic treatment difficult in patients with cirrhosis and hepatocellular carcinoma (HCC). We retrospectively evaluated the long-term effects of partial splenic embolization (PSE) with transarterial chemoembolization (TACE) in patients with HCC patients accompanied by thrombocytopenia.

Patients and Methods. Twenty-one patients with HCC complicated by severe thrombocytopenia (platelet count, <5.0 × 10^4/mm^3) were treated with PSE and TACE. Both the safety and platelet-increasing effect was evaluated in these patients.

Results. Seventeen of 21 patients (81.0%) showed increased platelet counts to ≥5.0 × 10^4/mm^3. Subsequently, 13 patients (61.9%) successfully received systemic chemotherapy. Platelet counts and serum levels of total bilirubin, as well as neutrophil counts, improved significantly one month after treatment. However, serum levels of albumin and hemoglobin decreased significantly one month after treatment. Severe adverse events, including acute liver failure and portal vein thrombus, were observed in two patients.

Conclusion. PSE with selective TACE made it possible for patients with HCC and severe thrombocytopenia to receive systemic chemotherapy. Although PSE with TACE was safe and tolerable for most patients, the extent of PSE with TACE in a wide area of the liver may increase the risk for fatal liver failure.

1. Introduction

Hepatocellular carcinoma (HCC) frequently develops in patients with cirrhosis. A considerable number of patients with HCC have thrombocytopenia secondary to hypersplenism. Since cirrhotic patients with severe thrombocytopenia are at greater risk for bleeding, treatments against HCC such as liver transplantation, resection, local ablation therapy, and transarterial chemoembolization (TACE) can be performed following a platelet transfusion in those patients. Therefore, there have been minimal differences in treatment strategy between patients with or without severe thrombocytopenia.

Sorafenib has shown survival benefit in patients with advanced HCC patients [1, 2]. However, sorafenib has several side effects such as decreased platelet counts and bleeding. Therefore, patients with severe thrombocytopenia are difficult to treat with sorafenib, and their treatment options are limited; they can only receive repetitive TACE or the best supportive treatment. These findings indicate that a new strategy to treat patients with advanced HCC and severe thrombocytopenia is needed.

Over the past 20 years, partial splenic embolization (PSE) has been an interventional radiological treatment for thrombocytopenia due to hypersplenism [3, 4]. This procedure usually results in an increase of platelet count. Recent reports show that PSE has a platelet-increasing effect and allows for the introduction of interferon therapy or systemic chemotherapy [5–8]. Therefore, we considered that PSE and TACE should be performed simultaneously to allow...
the introduction of systemic chemotherapy. The aim of this study was to assess the safety and effectiveness of PSE with TACE for patients with HCC and severe thrombocytopenia.

2. Patients and Methods

2.1. Patients. Medical records were retrieved for patients with HCC who were treated by PSE with TACE from November 2010 to October 2012 at Chiba University Hospital. Patients were included if they met the following criteria: (i) no indication for surgical resection or locoregional therapy, (ii) severe thrombocytopenia (platelet count, <5.0 × 10^4/mm³), (iii) Child-Pugh A or B, (iv) Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and (v) follow-up dynamic computed tomography (CT) 1 week after PSE with TACE. This study was approved by the Research Ethics Committee of Graduate School of Medicine, Chiba University.

2.2. PSE and TACE Procedure. All patients received sedative premedication with intravenous pentazocine and hydroxyzine. The procedure was performed under the local anesthesia using 1% xylocaine. A femoral artery approach was used for catheterization. Patients underwent baseline angiography of the celiac trunk, superior mesenteric artery, hepatic artery, and splenic artery using a peripheral arterial approach. First, we performed PSE according to Takatsuka method [9]. We placed a 4-Fr catheter into the splenic artery as near the splenic hilum as possible. A 2.2-, 2.4-, or 2.7-Fr microcatheter was coaxially advanced as distally as possible into a branch of the intrasplenic artery. We left the microcoils straight in the branch of the splenic artery. About 5-mm sized gelatin sponges were implanted proximal to the microcoils. Lower branches of the splenic artery were embolized using 0.035 inch coils (Tornado or Nester; Cook Inc., Bloomington, IN, USA). The length of coils was determined by that of the catheter. Premedication with intravenous pentazocine and hydroxyzine was used volume data from a portal phase multidetector row CT scan taken before and 1 week after the procedure. We performed the masking manually so that only the enhanced spleen remained on the workstation. Masking volume was calculated automatically by the workstation and we made it noninfarcted splenic volume.

2.3. Follow-Up. Dynamic CT was performed in all patients 1 week after the procedure to confirm the area of splenic infarction. When a patient with extrahepatic progression successfully showed an increase in platelet counts (≥5.0 × 10^4/mm³) 1 month after PSE with TACE, systemic chemotherapy was started. Follow-up dynamic CT was performed every 2-3 months. In patients without extrahepatic progression, dynamic CT was performed every 3-4 months after PSE with TACE to evaluate the therapeutic effect of TACE. When patients showed status that met the criteria proposed by the 2010 Japan Society of Hepatology Consensus Guidelines for TACE-refractorines [10] and an increase in platelet counts (≥5.0 × 10^4/mm³), systemic chemotherapy was started. In patients with HCC controlled by TACE, re-TACE with PSE was performed when HCC progressed. In patients with platelet counts sustained <5.0 × 10^4/mm³, re-TACE with PSE was performed until it could not be continued.

2.4. Calculation of Splenic Volume and Noninfarcted Splenic Volume. Splenic and noninfarcted splenic volumes in each patient were calculated using a three-dimensional workstation (Zio Station, Zio Software Inc., Tokyo, Japan). We used volume data from a portal phase multidetector row CT scan taken before and 1 week after the procedure. We performed the masking manually so that only the enhanced spleen remained on the workstation. Masking volume was calculated automatically by the workstation and we made it noninfarcted splenic volume.

2.5. Assessment of Adverse Events. We calculate the rate of adverse events in total of 32 PSE with TACE procedures in 21 patients to evaluate safety. Adverse events were evaluated according to the National Cancer institute Common Terminology Criteria for Adverse Events (CTCAE) ver. 4.0 (URL: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40).

2.6. Statistical Analysis. The change of neutrocyte counts, platelet counts, hemoglobin, albumin, prothrombin time-international normalized ratio (PT-INR), total bilirubin, and Child-Pugh score after PSE with TACE was evaluated before and after PSE with TACE. The paired t-test with a two-tailed test was used to compare between the data before and after PSE with TACE. All statistical analyses were performed using SPSS software (IBM SPSS Statistics 18; SPSS Japan).

3. Results

3.1. Patient Characteristics and Outcomes. Twenty-one patients (20 males and one female; mean age, 63.0 ± 9.1) with HCC and severe thrombocytopenia received PSE with TACE. Table 1 shows the characteristics of the 21 patients. The causes of chronic liver damage were hepatitis C virus (HCV) (n = 14), hepatitis B virus (HBV) (n = 3), and non-HBV and non-HCV (n = 4). Seventeen patients were in Barcelona Clinic Liver Cancer- (BCLC-) B stage and four patients were in BCLC-C stage. Mean splenic volume before PSE was 630.5 ± 239.0 mL. The mean platelet count before treatment was 4.2 ± 0.7 × 10^4/mL. Seventeen patients showed an increase in platelet counts ≥5.0 × 10^4/mm³ after PSE with TACE for 1 month, although the platelet counts in
| Number | Age  | Gender | Etiology | BCLC | C-P score | Splenic volume (mL) | Extent of necrosis (%) | Platelet count ($\times 10^4$/mm$^3$) | Hospital time (days) | Introduction of SC |
|--------|------|--------|----------|------|-----------|---------------------|------------------------|-------------------------|---------------------|------------------|
| 1      | 48   | M      | HCV      | B    | 5         | 578.4               | 45.3                   | 4.8                     | 11.7                | 11               |
| 2      | 60   | M      | HCV      | B    | 5         | 990.5               | 38.9                   | 3.9                     | 6.0                 | 10               |
| 3$^a$  | 64   | M      | NBNC     | B    | 7         | 1116.6              | 39.1                   | 3.9                     | 5.6                 | 11               |
| 4      | 57   | M      | HCV      | B    | 5         | 528.3               | 40.6                   | 2.7                     | 4.3                 | 13               |
| 5$^b$  | 65   | M      | HCV      | B    | 7         | 426.3               | 36.3                   | 2.4                     | ND                  | 12               |
| 6      | 48   | M      | HBV      | C    | 6         | 948.1               | 68.5                   | 4.8                     | 17.5                | 20               |
| 7      | 63   | M      | HCV      | B    | 6         | 656.7               | 72.5                   | 4.6                     | 15.1                | 15               |
| 8      | 78   | F      | HCV      | C    | 5         | 727.0               | 42.7                   | 3.7                     | 6.0                 | 9                |
| 9      | 55   | M      | HCV      | B    | 5         | 401.3               | 19.5                   | 4.9                     | 7.2                 | 12               |
| 10     | 82   | M      | NBNC     | B    | 8         | 472.4               | 40.2                   | 4.8                     | 8.7                 | 9                |
| 11     | 55   | M      | HBV      | B    | 7         | 896.8               | 21.0                   | 4.1                     | 6.1                 | 8                |
| 12$^c$ | 66   | M      | HCV      | B    | 7         | 815.9               | 30.2                   | 4.5                     | 4.6                 | 12               |
| 13     | 54   | M      | NBNC     | B    | 5         | 469.5               | 23.5                   | 4.6                     | 13.1                | 11               |
| 14     | 64   | M      | HBV      | B    | 5         | 469.5               | 20.1                   | 4.8                     | 13.7                | 9                |
| 15     | 64   | M      | HCV      | B    | 5         | 997.7               | 31.1                   | 3.9                     | 9.4                 | 10               |
| 16     | 61   | M      | HCV      | B    | 6         | 411.9               | 47.7                   | 4.6                     | 7.3                 | 9                |
| 17     | 76   | M      | HCV      | B    | 6         | 287.7               | 51.2                   | 4.4                     | 7.9                 | 12               |
| 18     | 53   | M      | HCV      | C    | 6         | 270.3               | 81.6                   | 4.9                     | 15.4                | 8                |
| 19$^d$ | 65   | M      | HCV      | B    | 8         | 785.5               | 77.0                   | 3.4                     | ND                  | 17               |
| 20     | 68   | M      | NBNC     | C    | 6         | 491.1               | 30.1                   | 3.4                     | 8.7                 | 20               |
| 21     | 77   | M      | HCV      | B    | 6         | 499.6               | 36.0                   | 4.8                     | 7.7                 | 10               |

| Mean   | 63.0 ± 9.1 | 630.5 ± 239.0 | 42.5 ± 17.6 | 4.2 ± 0.7 | 9.3 ± 3.8 | 11.4 ± 3.5 |

$^a$Complicated by portal vein thrombosis, $^b$lost to follow-up, $^c$no effect despite two additional PSE, $^d$complicated by lethal liver failure; BCLC, Barcelona Clinical Liver Center; C-P, Child-Pugh; SC, systemic chemotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; NBNC, non-HBV and non-HCV; PSE, partial splenic embolization; ND, not determined; NA, not applicable.
four patients remained <5.0 × 10⁴/mm³ (Figure 1). Among them, one died within 1 month because of liver failure, one showed portal vein thrombosis, one was lost to follow-up, and one exhibited totally no effect despite two additional PSE procedures. Four of 17 patients showed a successful increase in platelet counts and a simultaneous anti-HCC effect by TACE. Thereafter, they received on-demand TACE but not systemic chemotherapy. Eventually, 13 of 21 patients (61.9%) received systemic chemotherapy after first PSE with TACE. Notably, no patients withdrew or decreased the dose of their systemic chemotherapy because of thrombocytopenia. Four patients, who failed first-time systemic chemotherapy, received additional TACE with PSE before second-line systemic chemotherapy. One patient had variceal bleeding and received endoscopic variceal ligation and injection sclerotherapy before PSE and TACE. The 3 patients who experienced variceal bleeding after the procedure had severe liver dysfunction caused by HCC progression or were receiving sorafenib. Therefore, a causal connection between PSE and variceal bleeding was unclear.

3.2. Changes in Laboratory Data. Table 2 shows the changes in the neutrocyte count, platelet count, hemoglobin level, albumin level, PT-INR, total bilirubin level, and Child-Pugh score before treatment, one week later and one month later. The neutrocyte count increased significantly 1 week after treatment ($P = 0.001$). The albumin and hemoglobin levels decreased significantly 1 week after treatment ($P < 0.001$ and $P = 0.012$, resp.). Child-Pugh score deteriorated significantly 1 week after treatment ($P = 0.021$). The platelet count, total bilirubin level, and neutrocyte count improved significantly 1 month after treatment ($P < 0.001$, $P = 0.039$, and $P < 0.001$, resp.). Although the albumin and hemoglobin levels decreased significantly 1 month after treatment ($P = 0.036$ and $P = 0.046$, resp.), they improved compared with those of 1 week after treatment. However, neither PT-INR nor the Child-Pugh score changed significantly between before and after treatment.

3.3. Adverse Events. Major adverse events observed in 32 PSE with TACE procedures (in 21 patients) were shown in Table 3. Thirteen patients underwent the procedure once, 5 underwent the procedure twice, and 3 underwent the procedure thrice. In >30% procedures, increased levels of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), pain, ascites, and increased level of blood bilirubin were observed. Most of these adverse events improved without treatment or with only conservative treatment. PSE often causes severe complications such as splenic abscess, splenic rupture, pneumonia, refractory ascites, and pleural effusion [11, 12]. Neither splenic rupture nor pneumonia was observed in this study. Although splenic abscess was observed in one patient, he was improved by systemic administration of antibiotics. Although fourteen and 5 patients exhibited ascites and pleural effusion, respectively, these complications were temporary but not refractory.

One patient died because of liver failure. He had multiple HCCs that occupied >50% of the liver and underwent PSE with TACE in a wide area of the liver. One patient developed portal vein thrombosis. A reevaluation of the dynamic CT images revealed a mural thrombus in the portal vein before treatment. The thrombus resolved following warfarin administration.

4. Discussion

PSE is a useful procedure to improve hypersplenism and portal hypertension and their complications [13–18]. However, there are only a few reports that are available about PSE in patients with HCC [19–21]. In those reports, PSE with TACE was mainly performed to decrease complications of portal hypertension such as variceal bleeding. However, endoscopic therapy is the method most commonly used to prevent variceal bleeding. Considering that PSE has several severe complications [13, 22], the advantage of PSE was relatively small with regard to the treatment of gastroesophageal varices. Systemic chemotherapy using anticancer agents such
as sorafenib is now available for patients with advanced HCC. However, patients with severe thrombocytopenia, one of the complications of hypersplenism, cannot be treated with systemic chemotherapy because of chemotherapy-induced platelet-decreasing effect. Improving the severe thrombocytopenia enables those patients to receive systemic chemotherapy. No reports have considered the use of PSE to introduce systemic chemotherapy to patients with advanced HCC and severe thrombocytopenia. Thus, we evaluated the efficacy and safety of PSE for the purpose of introducing systemic chemotherapy to patients with HCC.

Table 2: Changes of the laboratory data between before treatment and 1 month after partial splenic embolization with transarterial chemoembolization.

|                            | Pretreatment Data | After 1 week Data | Mean of difference | P value | After 1 month Data | Mean of difference | P value |
|---------------------------|-------------------|-------------------|-------------------|---------|--------------------|-------------------|---------|
| Platelet counts ($\times 10^4/\text{mm}^3$) | 4.3 ± 0.6 | 5.6 ± 2.1 | 0.9 (−0.1 to 2.0) | 0.083 | 9.3 ± 4.0 | 4.9 (3.2 to 6.7) | <0.001 |
| Hemoglobin (g/dL)         | 12.3 ± 1.8 | 11.5 ± 2.0 | −0.7 (−1.2 to 0.2) | 0.012 | 11.8 ± 1.4 | −0.5 (−1.0 to 0.0) | 0.046 |
| Neutrocyte counts (/mm$^3$) | 1.878 ± 851 | 4.269 ± 2,797 | 2.241 (1,016 to 3,047) | 0.001 | 2,565 ± 1,055 | 687 (408 to 965) | <0.001 |
| Total bilirubin (mg/dL)   | 1.5 ± 0.8 | 1.7 ± 0.8 | 0.2 (0.0 to 0.5) | 0.063 | 1.3 ± 0.6 | −0.2 (−0.4 to 0.0) | 0.039 |
| Albumin (g/dL)            | 3.6 ± 0.2 | 3.2 ± 0.4 | −0.4 (−0.6 to −0.3) | <0.001 | 3.5 ± 0.3 | −0.1 (−0.3 to 0.0) | 0.036 |
| PT-INR                    | 1.16 ± 0.14 | 1.21 ± 0.21 | 0.03 (−0.01 to 0.07) | 0.123 | 1.12 ± 0.14 | −0.04 (−0.08 to 0.01) | 0.092 |
| Child-Pugh score          | 5.8 ± 0.9 | 6.3 ± 0.7 | 0.5 (0.1 to 0.9) | 0.021 | 5.9 ± 0.7 | 0.1 (−0.3 to 0.4) | 0.748 |

PT-INR, prothrombin time-international normalized ratio.

Table 3: Adverse events.

| Any grade | ≥grade 3 |
|-----------|---------|
| number (%) | number (%) |
| n = 32    |         |
| Increased AST/ALT levels | 24 (75) | 9 (28) |
| Pain       | 19 (59) | 0 |
| Increased ALP level | 15 (46) | 0 |
| Ascites    | 14 (44) | 0 |
| Increased bilirubin level | 11 (34) | 2 (6) |
| Anorexia   | 6 (19)  | 0 |
| Pleural effusion | 5 (16)  | 0 |
| Fever      | 4 (13)  | 0 |
| Decreased leukocyte counts | 3 (9)  | 2 (6) |
| Increased PT-INR | 3 (9)  | 2 (6) |
| Hyperkalemia | 3 (9)  | 1 (3) |
| Hypocalcemia | 3 (9)  | 0 |
| Constipation | 3 (9)  | 0 |
| Increased CPK level | 3 (9)  | 0 |
| Decreased neutrocyte counts | 2 (6)  | 2 (6) |
| Hyperuricemia | 2 (6)  | 1 (3) |
| Nausea     | 2 (6)   | 0 |
| Diarrhea   | 2 (6)   | 0 |
| Hematoma   | 2 (6)   | 0 |
| Increased creatinine level | 2 (6)  | 0 |
| Hepatic failure | 1 (3)  | 1 (3) |
| Portal vein thrombosis | 1 (3)  | 1 (3) |
| Splenic abscess | 1 (3)  | 0 |
| Splenic rupture | 0          | 0 |
| Pneumonia  | 0          | 0 |

AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; PT-INR, prothrombin time-international normalized ratio; CPK, creatine phosphokinase.
5. Conclusion

In conclusion, PSE for patients with HCC severe thrombocytopenia was useful to increase platelet counts and made it possible to introduce systemic chemotherapy. PSE with selective TACE is tolerable in most cases, but the extent of PSE with TACE in a wide area of the liver may increase the risk for fatal liver failure.

Conflict of Interests

None of the authors has conflict of interests.

References

[1] J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” New England Journal of Medicine, vol. 359, no. 4, pp. 378–390, 2008.
[2] A.-L. Cheng, Y.-K. Kang, Z. Chen et al., “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial,” The Lancet Oncology, vol. 10, no. 1, pp. 25–34, 2009.
[3] B. Sangro, I. Bilbao, I. Herrero et al., “Partial splenic embolization for the treatment of hypersplenism in cirrhosis,” Hepatology, vol. 18, no. 2, pp. 309–314, 1993.
[4] P. Stanley and T. C. Shen, “Partial embolization of the spleen in patients with thalassemia,” Journal of Vascular and Interventional Radiology, vol. 6, no. 1, pp. 137–142, 1995.
[5] Y. Miyake, M. Ando, E. Kaji, T. Toyokawa, M. Nakatsu, and M. Hirohata, “Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia,” Hepatology Research, vol. 38, no. 10, pp. 980–986, 2008.
[6] C. R. Kauffman, A. Mahvash, S. Kopetz, R. A. Wolff, J. Ensor, and M. J. Wallace, “Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy,” Cancer, vol. 112, no. 10, pp. 2283–2288, 2008.
[7] M. Kato, N. Shimohashi, J. Ouchi et al., “Partial splenic embolization facilitates completion of interferon therapy in patients with chronic HCV infection and hypersplenism,” Journal of Gastroenterology, vol. 40, no. 11, pp. 1076–1077, 2005.
[8] M. Takahara, Y. Miyake, H. Miyatake et al., “Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia,” Internal Medicine, vol. 50, no. 22, pp. 2731–2736, 2011.
[9] H. Shimizu, K. Takatsuka, A. Yoshida, E. Yoshimatsu, K. Matsui, and S. Iwabuchi, “Partial splenic embolization reverses insulin resistance in patients with liver cirrhosis,” Internal Medicine, vol. 48, no. 10, pp. 747–751, 2009.
[10] M. Kudo, N. Izumi, N. Kokudo et al., “Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of hepatology (JSH) 2010 updated version,” Digestive Diseases, vol. 29, no. 3, pp. 339–364, 2011.
[11] R. Shah, G. H. Mahour, E. G. Ford, and P. Stanley, “Partial splenic embolization: an effective alternative to splenectomy for hypersplenism,” The American Surgeon, vol. 56, no. 12, pp. 774–777, 1990.
[12] K. Zhu, X. Meng, J. Qian et al., “Partial splenic embolization for hypersplenism in cirrhosis: a long-term outcome in 62 patients,” Digestive and Liver Disease, vol. 41, no. 6, pp. 411–416, 2009.
[13] G. N’Kontchou, O. Seror, V. Bourciez et al., “Partial splenic embolization in patients with cirrhosis: efficacy, tolerance and long-term outcome in 32 patients,” European Journal of Gastroenterology and Hepatology, vol. 17, no. 2, pp. 179–184, 2005.
[14] K. G. Koconis, H. Singh, and G. Soares, “Partial splenic embolization in the treatment of patients with portal hypertension: a review of the English language literature,” Journal of Vascular and Interventional Radiology, vol. 18, no. 4, pp. 463–481, 2007.
[15] M. Miyazaki, H. Itoh, T. Kaio et al., “Partial splenic embolization for the treatment of chronic idiopathic thrombocytopenic purpura,” The American Journal of Roentgenology, vol. 163, no. 1, pp. 123–126, 1994.
[16] A. Moreno, R. Bárceña, J. Blázquez et al., “Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV/HCV patients prior to pegylated interferon and ribavirin,” Antiviral Therapy, vol. 9, no. 6, pp. 1027–1030, 2004.
[17] R. Pandey, R. Garg, V. Darlong, J. Punj, and A. Kumar, “Role of splenic artery partial embolization in a patient with portal hypertension and pancytopenia undergoing hysterectomy under anesthesia,” AAN journal, vol. 80, no. 2, pp. 96–98, 2012.
[18] J. I. Gu, X. H. He, W. T. Li et al., “Safety and efficacy of splenic artery coil embolization for hypersplenism in liver cirrhosis,” Acta Radiologica, vol. 53, no. 8, pp. 862–867, 2012.
[19] R. Roversi, S. Ricci, P. I. Gambari et al., “Splenic embolization and hepatic chemoembolization: combined transcatheter treatment of hepatocellular carcinoma in cirrhosis with hypersplenism,” La Radiologia Medica, vol. 85, no. 4, pp. 444–449, 1993.
[20] M.-J. Han, H.-G. Zhao, K. Ren, D.-C. Zhao, K. Xu, and X.-T. Zhang, “Partial splenic embolization for hypersplenism concomitant with or after arterial embolization of hepatocellular carcinoma in 30 patients,” Cardiovascular and Interventional Radiology, vol. 20, no. 2, pp. 125–127, 1997.
[21] J.-H. Huang, F. Gao, Y.-K. Gu, W.-Q. Li, and L.-W. Lu, “Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization,” World Journal of Gastroenterology, vol. 13, no. 48, pp. 6593–6597, 2007.
[22] T. Sakai, K. Shiraki, H. Inoue et al., “Complications of partial splenic embolization in cirrhotic patients,” Digestive Diseases and Sciences, vol. 47, no. 2, pp. 388–391, 2002.